We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Read MoreHide Full Article
Key Takeaways
ALC posted Q1 2026 sales gains: Surgical $1.46B and Vision Care $1.23B, both up 6% cc.
Alcon's Unity launch helped equipment sales jump, with an expanding installed base and post-ASCRS orders.
ALC flagged $33M Q1 tariffs and 120 bps gross-margin drag; 2026 net tariff hit seen at $100-$150M.
Alcon’s (ALC - Free Report) Vision Care business continues to gain from its diverse portfolio of contact lenses and ocular health products. Growth momentum within the Surgical business is poised to boost the top line in the upcoming quarters. Meanwhile, adverse macroeconomic conditions and intense competition may harm the company’s operations.
In the past year, this Zacks Rank #3 (Hold) stock has dipped 22.3% compared with the industry’s 7.3% decline. The S&P 500 composite has risen 31.8% in the same time frame.
The renowned pharmaceutical and medical device manufacturer has a market capitalization of $32.77 billion. ALC’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 3.7%.
Let’s delve deeper.
Upsides for ALC
Surgical Business Momentum: Alcon continues to refresh its cataract workflow and intraocular lens lineup, which supports share gains even as procedure growth remains uneven. In the first quarter of 2026, Surgical sales were $1.46 billion, up 6% at constant currency, with equipment up 23% and supported by the recent Unity launch.
Management highlighted expansion of the Unity installed base and pointed to a strong post-ASCRS order pipeline, which should support equipment growth as more sites convert. Consumables sales were up 4% at constant currency, aided by price increases despite softer cataract market conditions.
Within implantables, first-quarter sales were $438 million, up 1% at constant currency, reflecting the U.S. performance of PanOptix Pro and competitive pressures internationally. The company also launched TruPlus with a toric option, which broadens its monofocal plus offering.
Vision Care Returns to Growth: Vision Care continues to benefit from a shift toward newer contact lens offerings and expansion in dry eye, which supports a steadier growth profile over time.
In the first quarter of 2026, Vision Care sales were $1.23 billion, up 6% at constant currency, with contact lenses up 4% and ocular health up 10% at constant currency. After expanding the TOTAL 30 family last year to cover all major modalities — sphere, toric and multifocal — in February 2026, the company introduced a multifocal toric lens for presbyopes patients with astigmatism.
Alcon’s PRECISION7 remains a key weekly platform for patients who are not candidates for daily disposables. In ocular health, Systane delivered high single-digit growth in the quarter, and multi-dose preservative-free formats grew more than 20% year over year.
Image Source: Zacks Investment Research
Downsides for ALC
Macroeconomic Pressure Stays: Alcon remains exposed to geopolitical and trade volatility that can disrupt supply chains and raise input costs, particularly as tariffs continue to evolve. In the first quarter of 2026, incremental tariffs in the U.S. and China totaled $33 million, and management cited a 120 basis points drag on core gross margin. For 2026, management’s outlook assumes a net tariff impact of about $100 million to $150 million and excludes any potential refunds.
The company disclosed that it has paid approximately $64 million under invalidated IEEPA tariffs, though no refunds have been recorded due to uncertainty surrounding timing and recoverability.
Tough Competitive Landscape: Competition remains intense across both segments and is showing up most clearly where Alcon is defending share outside the United States and managing mix transitions. In the first quarter of 2026, implantables grew 1% at constant currency as PanOptix Pro's strength was offset by competitive pressure in international markets and lower sales in surgical glaucoma. In Vision Care, contact lenses grew 4% at constant currency, but management cited declines in legacy products as it reduced promotional activity.
ALC Stock Estimate Trend
The Zacks Consensus Estimate for 2026 earnings per share has moved north 2 cents to $3.48 in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $11.05 billion, suggesting a 7.1% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s -3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
Integra LifeSciences, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 16% against the industry’s -3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Key Takeaways
Alcon’s (ALC - Free Report) Vision Care business continues to gain from its diverse portfolio of contact lenses and ocular health products. Growth momentum within the Surgical business is poised to boost the top line in the upcoming quarters. Meanwhile, adverse macroeconomic conditions and intense competition may harm the company’s operations.
In the past year, this Zacks Rank #3 (Hold) stock has dipped 22.3% compared with the industry’s 7.3% decline. The S&P 500 composite has risen 31.8% in the same time frame.
The renowned pharmaceutical and medical device manufacturer has a market capitalization of $32.77 billion. ALC’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 3.7%.
Let’s delve deeper.
Upsides for ALC
Surgical Business Momentum: Alcon continues to refresh its cataract workflow and intraocular lens lineup, which supports share gains even as procedure growth remains uneven. In the first quarter of 2026, Surgical sales were $1.46 billion, up 6% at constant currency, with equipment up 23% and supported by the recent Unity launch.
Management highlighted expansion of the Unity installed base and pointed to a strong post-ASCRS order pipeline, which should support equipment growth as more sites convert. Consumables sales were up 4% at constant currency, aided by price increases despite softer cataract market conditions.
Within implantables, first-quarter sales were $438 million, up 1% at constant currency, reflecting the U.S. performance of PanOptix Pro and competitive pressures internationally. The company also launched TruPlus with a toric option, which broadens its monofocal plus offering.
Vision Care Returns to Growth: Vision Care continues to benefit from a shift toward newer contact lens offerings and expansion in dry eye, which supports a steadier growth profile over time.
In the first quarter of 2026, Vision Care sales were $1.23 billion, up 6% at constant currency, with contact lenses up 4% and ocular health up 10% at constant currency. After expanding the TOTAL 30 family last year to cover all major modalities — sphere, toric and multifocal — in February 2026, the company introduced a multifocal toric lens for presbyopes patients with astigmatism.
Alcon’s PRECISION7 remains a key weekly platform for patients who are not candidates for daily disposables. In ocular health, Systane delivered high single-digit growth in the quarter, and multi-dose preservative-free formats grew more than 20% year over year.
Image Source: Zacks Investment Research
Downsides for ALC
Macroeconomic Pressure Stays: Alcon remains exposed to geopolitical and trade volatility that can disrupt supply chains and raise input costs, particularly as tariffs continue to evolve. In the first quarter of 2026, incremental tariffs in the U.S. and China totaled $33 million, and management cited a 120 basis points drag on core gross margin. For 2026, management’s outlook assumes a net tariff impact of about $100 million to $150 million and excludes any potential refunds.
The company disclosed that it has paid approximately $64 million under invalidated IEEPA tariffs, though no refunds have been recorded due to uncertainty surrounding timing and recoverability.
Tough Competitive Landscape: Competition remains intense across both segments and is showing up most clearly where Alcon is defending share outside the United States and managing mix transitions. In the first quarter of 2026, implantables grew 1% at constant currency as PanOptix Pro's strength was offset by competitive pressure in international markets and lower sales in surgical glaucoma. In Vision Care, contact lenses grew 4% at constant currency, but management cited declines in legacy products as it reduced promotional activity.
ALC Stock Estimate Trend
The Zacks Consensus Estimate for 2026 earnings per share has moved north 2 cents to $3.48 in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $11.05 billion, suggesting a 7.1% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s -3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Integra LifeSciences, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 16% against the industry’s -3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.